Skip to main content

Advertisement

SpringerLink
Log in

Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Coagulative dysfunction is frequently observed among patients with extranodal nasal-type natural killer/T cell lymphoma (NKTCL) in our clinical practice. However, the true prognostic value of coagulation factors in patients with NKTCL has not been evaluated systemically. Data for patients with stage I/II NKTCL who were treated in the Cancer Hospital, Chinese Academy of Medical Sciences, from January 2008 to January 2019 were collected retrospectively. The patients enrolled in this study were initially diagnosed as having early-stage disease. The patients’ baseline characteristics and pretreatment laboratory tests for coagulation function, including fibrinogen (FIB) and d-dimer (d-D), were reviewed and analyzed. The influence of coagulative factors on the responses and prognosis of patients with early-stage NKTCL was evaluated. Among 394 patients assessed, 154 were included in this study. Abnormal coagulation function was found in nearly half of the patients (48.1%). Univariate analysis showed that reduced complete remission (CR) was associated with elevated d-D (P = 0.001) and elevated FIB levels (P = 0.006). The d-D level was demonstrated as associated with unfavorable progression-free survival (PFS) (P = 0.003) and overall survival (OS) (P = 0.002). Multivariate analysis indicated that an elevated d-D level was an independent factor for poor clinical response (P = 0.019), PFS (P = 0.046), and OS (P = 0.024). Elevated pretreatment levels of coagulation factors, especially d-D and plasma FIB, are unfavorable predictors for clinical response, OS, and PFS in early-stage NKTCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Yang Y, Zhang YJ, Zhu Y et al (2015) Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Int J Radiat Oncol Biol Phys 93S:E448–E449

    Article  Google Scholar 

  2. Yang Y, Zhu Y, Cao JZ, Zhang YJ, Xu LM, Yuan ZY, Wu JX, Wang W, Wu T, Lu B, Zhu SY, Qian LT, Zhang FQ, Hou XR, Li YX (2015) Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. BLOOD 126:1424–1432

    Article  CAS  PubMed  Google Scholar 

  3. SHIPP MA, HARRINGTON DP, ANDERSON JR et al (1993) A predictive model for aggressive non-Hodgkins-lymphoma. N Engl J Med 329:987–994

    Article  Google Scholar 

  4. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612–618

    Article  PubMed  Google Scholar 

  5. Ye Z, Cao Q, Niu G, Liang Y, Liu Y, Jiang L, Yu X, Han A (2013) p63 and p53 expression in extranodal NK/T cell lymphoma, nasal type. J Clin Pathol 66:676–680

    Article  CAS  PubMed  Google Scholar 

  6. Kim SJ, Kim BS, Choi CW, Choi J, Kim I, Lee YH, Kim JS (2007) Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 18:1382–1387

    Article  CAS  PubMed  Google Scholar 

  7. Bi XW, Wang L, Zhang WW, Yan SM, Sun P, Xia Y, Li ZM, Jiang WQ (2016) The pretreatment albumin to globulin ratio predicts survival in patients with natural killer/T-cell lymphoma. PeerJ 4:e1742

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jaffe ES (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematol Am Soc Hematol Educ Program 523–31. https://doi.org/10.1182/asheducation-2009.1.523

  9. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R, for the International Peripheral T-Cell Lymphoma Project (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113:3931–3937

    Article  CAS  PubMed  Google Scholar 

  10. Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d’Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS (2016) A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol 17:389–400

    Article  CAS  PubMed  Google Scholar 

  11. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin’s Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068

    Article  PubMed  PubMed Central  Google Scholar 

  12. Fan S, Zhao G, An G (2019) High pretreatment plasma D-dimer levels are associated with shorter overall survival in patients with small cell lung cancer. J Int Med Res 47:215–224

    Article  CAS  PubMed  Google Scholar 

  13. Liu FT, Gao H, Wu CW, Zhu ZM (2017) The association of plasma fibrinogen with clinicopathological features and prognosis in esophageal cancer patients. Oncotarget 8:93029–93038

    Article  PubMed  PubMed Central  Google Scholar 

  14. Liu P, Zhu Y, Liu L (2015) Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma. Onco Targets Ther 8:1335–1340

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sun ZQ, Han XN, Wang HJ, Tang Y, Zhao ZL, Qu YL, Xu RW, Liu YY, Yu XB (2014) Prognostic significance of preoperative fibrinogen in patients with colon cancer. World J Gastroenterol 20:8583–8591

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prové A, Lemmens J, Vermeulen P (2002) Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 86:389–395

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Sanfilippo K, Wang T, Gage B et al (2016) Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thromb Res 143:86–90

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Borg IH, Bendtsen MD, Bogsted M et al (2016) Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 57:2771–2776

    Article  CAS  PubMed  Google Scholar 

  19. Colombo R, Gallipoli P, Castelli R (2014) Thrombosis and hemostatic abnormalities in hematological malignancies. Clin Lymphoma Myeloma Leuk 14:441–450

    Article  PubMed  Google Scholar 

  20. Kang HJ, Bae K, Kim JH, Cho CK, Yoo HS (2018) Correlation between natural killer cell activity and systemic inflammatory markers for heterogeneous cancer patients treated with wheel balance cancer therapy. Integr Cancer Ther 17:322–331

    Article  PubMed  Google Scholar 

  21. Kattula S, Byrnes JR, Wolberg AS (2017) Fibrinogen and fibrin in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 37:e13–e21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Martino MM, Briquez PS, Ranga A, Lutolf MP, Hubbell JA (2013) Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci U S A 110:4563–4568

    Article  PubMed  PubMed Central  Google Scholar 

  23. Zheng S, Shen J, Jiao Y, Liu Y, Zhang C, Wei M, Hao S, Zeng X (2009) Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci 100:859–865

    Article  CAS  PubMed  Google Scholar 

  24. Bi XW, Wang L, Zhang WW et al (2016) High pretreatment D-dimer levels correlate with adverse clinical features and predict poor survival in patients with natural killer/T-cell lymphoma. PLoS One 11:e152842

    Google Scholar 

  25. Diao D, Cheng Y, Song Y, Zhang H, Zhou Z, Dang C (2017) D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer. BMC Cancer 17:56

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by the special fund of Beijing Hope Run Project (grant number, LC2014L11).

Author information

Authors and Affiliations

  1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China

    Yue Chai, Fei Qi, Bo Chen, Lin Gui, Jianliang Yang, Shunan Qi, Yongwen Song, Yexiong Li, Yuce Wei & Mei Dong

Authors
  1. Yue Chai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fei Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bo Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lin Gui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jianliang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shunan Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yongwen Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yexiong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuce Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mei Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mei Dong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chai, Y., Qi, F., Chen, B. et al. Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma. Ann Hematol 99, 1303–1309 (2020). https://doi.org/10.1007/s00277-020-04035-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04035-0

Keywords

Search

Navigation